Name: supra-ABE (Adenine Base Editor)
Brand: KACTUS
Price: 458.0 USD
Availability: OutOfStock

‌Sanger sequencing and EditR analysis demonstrate that supra-ABE efficiently mediates A-to-G conversion in the start codon (ATG) of PD1 and CD3G genes, disrupting translation initiation and achieving approximately 90% knockout efficiency.

‌Sanger sequencing and EditR analysis results show that supra-ABE can convert A to G within the editing window, with varying editing efficiencies for adenine (A) bases at different positions—the highest editing efficiency exceeds 90%. Additionally, the editing window of supra-ABE is wider than that of ABE8e.

FACS analysis demonstrated that supra-ABE efficiently knocked out the CD3G protein, achieving a knockout efficiency of 90.21%, whereas ABE8e exhibited no editing activity within the editing range at this site.

SEC-HPLC analysis confirms supra-ABE purity exceeding 95.0%.

Bis-Tris PAGE analysis confirms supra-ABE purity exceeding 95.0%.

Description: supra-ABE is a next-generation adenine base editor featuring the patented eMa-TadA deaminase embedded in Cas9 nickase, enabling precise A-to-G edits without double-strand breaks. High efficiency, broad editing windows, and low off-target effects make it ideal for gene and cell therapy applications.
Quality: Research-Grade
Purity: ≥ 80%

Catalog #CAS-EE145

Size

100UG

1MG

Order now, ships by:

Product Description

supra-ABE is an adenine base editor comprising the exclusively patented adenine deaminase eMa-TadA fused with Cas9 nickase (Cas9n), where eMa-TadA is embedded within Cas9n. The eMa-TadA deaminase catalyzes the deamination of adenine in DNA, converting it to inosine. During DNA replication, inosine is recognized as guanine, enabling A-to-G base substitution within editing window positions 4-14 without requiring a donor template or inducing DNA double-strand breaks. The supra-ABE system demonstrates high editing activity, broad effective editing windows, and low off-target rates, making it a versatile tool for applications in cell and gene therapy.

Product Background

Applications
‌1. Gene Knockout‌: Gene knockout is achieved by mutating the start codon ATG or altering the canonical splice sites GT-AG through A-to-G or T-to-C substitutions, thereby disrupting gene function.
‌2. Gene Correction‌: Precise repair of pathogenic single-base mutations (A-to-G or T-to-C substitutions at specific adenine or thymine sites) enables restoration of normal gene function through single-base editing.

Concentration	10 mg/mL
Source	E. coli
Molecular Weight	183.83 kDa
Purity	≥ 80%
Endotoxin	≤ 10.0 EU/mg
Quality Standards	Concentration: 9.0-11.0mg/mL Purity (Bis-Tris PAGE): ≥ 80.0% Purity (SEC-HPLC): ≥ 80.0% Endotoxin: ≤ 10.0EU/mg

Form	Liquid
Formulation	30mM Tris, 300mM NaCl, 50% Glycerol, 0.1mM EDTA, 5mM DTT, pH 7.8
Stability And Storage	Transport on dry ice. Store at -80 ±10°C. Avoid repeated freezing and thawing.

	‌Sanger sequencing and EditR analysis demonstrate that supra-ABE efficiently mediates A-to-G conversion in the start codon (ATG) of PD1 and CD3G genes, disrupting translation initiation and achieving approximately 90% knockout efficiency.
	‌Sanger sequencing and EditR analysis results show that supra-ABE can convert A to G within the editing window, with varying editing efficiencies for adenine (A) bases at different positions—the highest editing efficiency exceeds 90%. Additionally, the editing window of supra-ABE is wider than that of ABE8e.
	FACS analysis demonstrated that supra-ABE efficiently knocked out the CD3G protein, achieving a knockout efficiency of 90.21%, whereas ABE8e exhibited no editing activity within the editing range at this site.
	SEC-HPLC analysis confirms supra-ABE purity exceeding 95.0%.
	Bis-Tris PAGE analysis confirms supra-ABE purity exceeding 95.0%.